Serial Buyers LifeStance, ARC Health, Beacon Behavioral Reveal Their Acquisition Playbooks for 2026
LifeStance Health, ARC Health, and Beacon Behavioral Partners have refined their acquisition strategies, shifting from pure growth to focusing on integration, fit, and sustainability. LifeStance is returning to M&A with a focus on tuck-in deals that expand outpatient footprints and service lines, while ARC Health and Beacon Behavioral are prioritizing strong partner alignment and clinical quality. All three companies emphasize culture and compliance fit, and avoid targets with weak compliance, low scalability, or those outside their specialized outpatient mental health focus.
3 Reasons to Avoid LFST and 1 Stock to Buy Instead
This article analyzes why investors should be cautious about LifeStance Health Group (LFST), despite its recent stock price increase. The author outlines three reasons: limited distribution channels due to its small size, breakeven free cash flow hindering reinvestment, and negative return on invested capital from past growth initiatives. The article concludes that LFST's business quality is subpar and suggests investing in a more established, "all-weather" company instead, mentioning the owner of Taco Bell.
Preliminary Approval Granted in LifeStance Data Privacy Case
A federal court in Arizona has granted preliminary approval for a class action settlement in the Strong v. LifeStance Health Group Inc. data privacy case. The lawsuit alleged that LifeStance disclosed patients' personal information through website tracking technologies. The settlement includes two subclasses of LifeStance's patient population, and a final approval hearing is scheduled for October 2, 2026.
LifeStance Health Group (LFST) is a great momentum stock: Should you buy?
This article asks whether LifeStance Health Group (LFST) is a good momentum stock to buy. It likely analyzes the company's recent stock performance and valuation to determine its investment potential.
TPG entities listed with 29.3% of LifeStance (LFST) common stock
TPG-affiliated entities, including TPG GP A, LLC, James G. Coulter, and Jon Winkelried, have reported a 29.3% stake in LifeStance Health Group, Inc. (LFST) through an amended Schedule 13G/A filing. This includes 111,744,614 shares of common stock, with shared voting and shared dispositive power, based on 381,834,432 shares outstanding as of May 12, 2026. The filing highlights the ownership structure through TPG VIII Lynnwood and disclaims beneficial ownership beyond pecuniary interest for the individual reporting persons.
Summit funds tied to LifeStance (LFST) director sell 5.9M shares
LifeStance Health Group, Inc. director Darren M. Black reported an indirect open-market sale of 5,899,661 shares of common stock at $8.02 per share through Summit Partners-affiliated investment entities. After these transactions, the entities collectively hold 23,310,115 shares. The sale, valued at over $47 million, was completed on May 12, 2026, and was reported via a Form 4 SEC filing.
Insider Selling: LifeStance Health Group (NASDAQ:LFST) Director Sells 575,034 Shares of Stock
LifeStance Health Group (NASDAQ:LFST) director Robert Bessler recently sold 575,034 shares of the company's stock for approximately $4.61 million, reducing his ownership by 36.81%. This sale follows other transactions by Bessler in April and May. Despite these insider sales, analysts maintain a "Buy" consensus rating for LFST with an average price target of $9.86, following strong first-quarter results and a $100 million share buyback authorization.
LifeStance Health director Darren Black sells $47.3m in stock
LifeStance Health Group director Darren M. Black indirectly sold 5,899,661 shares of common stock for approximately $47.3 million through various Summit Partners funds. Following the sale, entities beneficially owned by Mr. Black still hold over 23 million shares. The transaction occurred as the stock experienced a challenging week with an 11% decline, despite strong six-month and one-year returns, and an InvestingPro analysis suggesting it remains undervalued.
LifeStance Health director Darren Black sells $47.3m in stock
Darren M. Black, a director at LifeStance Health Group, Inc. (NASDAQ:LFST), indirectly sold over 5.8 million shares of common stock for approximately $47.3 million. The transaction, executed through various Summit Partners funds, occurred on May 12, 2026, with shares priced at $8.02. Despite a recent weekly decline, the stock has shown strong six-month and year-over-year returns, and InvestingPro suggests it remains undervalued.
LifeStance Health director Robert Bessler sells $4.6m in shares
LifeStance Health Group director Robert Bessler sold approximately $4.61 million worth of common stock on May 12, 2026, through indirect holdings. This sale, at $8.02 per share, comes despite the company's recent strong Q1 2026 financial results, which included an earnings per share of $0.04 and revenue of $403.48 million, both exceeding expectations. Bessler retains significant indirect and direct holdings in the company after these transactions.
LifeStance Health director Eric Shuey sells $1.95m in stock
LifeStance Health director Eric Shuey sold 243,362 shares of common stock for approximately $1.95 million. The sale was made on May 12, 2026, by the Eric Shuey Gift Trust, reducing its holdings to 867,562 shares. Despite a recent stock decline, shares are up 41% over the past year, and the company recently reported strong Q1 2026 financial results.
Director-linked LLCs trim LifeStance (LFST) stakes with 575,034-share sale
LifeStance Health Group director Robert Bessler's associated entities, Shama LLC and Vitthal LLC, collectively sold 575,034 shares of LFST common stock at $8.02 per share on May 12, 2026. These indirect open-market sales amounted to over $4.6 million. Following the transactions, the LLCs still hold significant stakes in the company, though Bessler disclaims beneficial ownership except to the extent of his pecuniary interest.
[Form 4] LifeStance Health Group, Inc. Insider Trading Activity
A Form 4 filing revealed that the Eric Shuey Gift Trust, linked to LifeStance Health Group director Eric Shuey, sold 243,362 shares of LifeStance common stock at $8.02 per share in an open-market transaction. Following this sale, the trust indirectly holds 867,562 shares, while Eric Shuey directly holds 93,982 shares. Shuey disclaims beneficial ownership of the trust-held securities except for his pecuniary interest.
5 Revealing Analyst Questions From LifeStance Health Group’s Q1 Earnings Call
LifeStance Health Group's Q1 results showed strong revenue growth and margin expansion, driven by clinician recruitment, productivity, and technology use. The company raised its full-year revenue and EBITDA guidance. This article highlights five key analyst questions and management's answers regarding clinician growth, productivity, patient conversion, leveraging clinical outcomes, and expansion strategies.
Vanguard Group Inc. Raises Position in LifeStance Health Group, Inc. $LFST
Vanguard Group Inc. significantly increased its stake in LifeStance Health Group (NASDAQ:LFST) by 21.1% in the fourth quarter, bringing its total holdings to 17.7 million shares valued at $124.6 million. This increase happened despite notable insider selling from directors, with the company also reporting better-than-expected first-quarter earnings and authorizing a $100 million share repurchase program. Analysts currently have a "Buy" consensus rating for LifeStance Health Group, with a consensus price target of $10.00.
LFST: Hybrid mental health provider targets mid-teens EBITDA margins by 2028 amid strong industry growth
LifeStance Health Group (LFST), a hybrid mental health provider, is poised for significant growth driven by rising demand, reduced stigma, and a shift towards insurance-based care in outpatient mental health. The company is achieving high patient satisfaction and strong financial performance, with a target of mid-teens EBITDA margins by 2028. This information is based on their Bank of America Global Healthcare Conference 2026 Audio Transcript.
LifeStance Health Group (LFST) is a Great Momentum Stock: Should You Buy?
LifeStance Health Group (LFST) has been identified as a strong momentum stock with a Zacks Rank of #1 (Strong Buy) and a Momentum Style Score of "A". The company's stock has shown favorable short-term and long-term price performance against its industry and the S&P 500. Additionally, positive earnings estimate revisions further support its promising outlook for investors seeking near-term growth.
[8-K] LifeStance Health Group, Inc. Reports Material Event
LifeStance Health Group, Inc. (NASDAQ: LFST) filed an 8-K report detailing an underwritten offering of 35,000,000 shares of common stock by existing selling stockholders. The company itself did not receive any proceeds from this sale but separately agreed to repurchase 6,000,000 of these shares from the underwriter. The offering closed on May 12, 2026, and was managed by J.P. Morgan Securities LLC.
LifeStance Health Group completes offering of 35 million shares by selling stockholders
LifeStance Health Group (NASDAQ:LFST) announced the completion of an underwritten public offering of 35,000,000 shares of its common stock by selling stockholders. The company did not receive any proceeds from this sale but agreed to repurchase 6,000,000 shares from the selling stockholders via the underwriter at the same price. This offering follows recent positive financial results, where the company exceeded Q1 2026 earnings and revenue estimates.
LifeStance Health Group completes offering of 35 million shares by selling stockholders
LifeStance Health Group (NASDAQ:LFST) has completed an underwritten public offering of 35 million shares by selling stockholders. The company did not receive any proceeds from this sale but agreed to repurchase 6 million shares from the underwriter. This follows recent strong financial results, including outperforming Q1 2026 market expectations with higher EPS and revenue.
LifeStance Health Group prices secondary offering at $8.15 per share
This article announces that LifeStance Health Group has priced its secondary offering at $8.15 per share. No further details are available in the provided content.
LifeStance Health director Robert Bessler sells $641,250 in shares
LifeStance Health director Robert Bessler sold 75,000 shares of common stock for $641,250 on May 7, 2026, through Vitthal LLC and Shama LLC. Despite the sale, Bessler retains significant indirect and direct holdings. This transaction follows strong Q1 2026 results for LifeStance Health, which also announced a secondary public offering and a share repurchase plan.
75K LifeStance (NASDAQ: LFST) shares sold by director-linked entities
Entities linked to LifeStance Health Group director Robert Bessler sold a total of 75,000 shares of common stock in open-market transactions. Shama LLC and Vitthal LLC each sold 37,500 shares at a weighted average price of $8.55, with transaction prices ranging from $8.40 to $8.89. After these sales, the entities continue to hold significant shares, and Bessler disclaims beneficial ownership of indirect holdings beyond his pecuniary interest.
LifeStance Health Group, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:LFST) 2026-05-10
LifeStance Health Group, Inc. (LFST) reported its Q1 2026 earnings, with EPS of $0.07 beating estimates by $0.01. The company's revenue reached $403.48M, exceeding expectations by $17.36M and representing a 21.17% year-over-year increase. The article mentions that a slide deck was released by LifeStance Health Group, Inc. in conjunction with their earnings call.
LifeStance Health Stock Slides After $8.15 Secondary Pricing
LifeStance Health Group Inc. (NASDAQ: LFST) stock dropped by 13.72% following the pricing of a 35-million-share secondary offering at $8.15 by existing holders, with no new capital for the company. Despite improved Q1 2026 financials, the large share sale and insider selling created downward pressure, establishing a resistance zone between $8.00 and $8.15. The company plans to repurchase 6 million shares at the offering price, indicating some management support around that level.
[SCHEDULE 13G/A] LifeStance Health Group, Inc. Amended Passive Investment Disclosure
Summit Partners and affiliated funds have filed an amended passive investment disclosure (Schedule 13G/A) for LifeStance Health Group, Inc. (NASDAQ: LFST). The filing shows Summit Partners, L.P. with shared beneficial ownership of 29,209,776 shares, representing 7.49% of the company's common stock, based on 389,783,210 shares outstanding as of February 17, 2026. Various Summit Growth Equity Funds and other related entities are also listed with shared voting and dispositive power.
[424B7] LifeStance Health Group, Inc. Prospectus Filed Pursuant to Rule 424(b)(7)
LifeStance Health Group, Inc. (LFST) has filed a 424(b)(7) prospectus for the resale of 35,000,000 shares of common stock by selling stockholders. The company itself is not selling any shares but intends to repurchase 6,000,000 shares from the underwriter, J.P. Morgan, at the public offering price of $8.15 per share. This repurchase, contingent on the offering's closing, will reduce the number of outstanding shares.
LifeStance Health Group (LFST) Stock Trades Down, Here Is Why
Shares of LifeStance Health (LFST) dropped 11.7% following the announcement of a large secondary offering of 35 million shares by existing shareholders at $8.15 each. This news overshadowed a strong first-quarter report where the company's revenue grew 21% year-over-year and it raised its full-year financial outlook, which had initially caused the stock to rally. The company also stated it would repurchase 6 million shares from the sellers, but the market reacted negatively to the increased supply of stock.
Why LifeStance Health Group Zoomed 20% Higher Today
LifeStance Health Group (LFST) saw its stock jump over 20% after reporting a strong first quarter, significantly beating analyst expectations for revenue and net income. The mental health services provider also raised its full-year guidance, attributing its success to the increasing demand for mental healthcare. The company's CEO highlighted its differentiated model and positive patient outcomes in supporting its growth trajectory.
LifeStance Health LFST Slides As 35M-Share Secondary Hits Market
LifeStance Health Group Inc. (LFST) stock slid by 12.09% following the announcement of a large 35 million-share secondary offering by existing shareholders, priced at the bottom end of its range at $8.15. While the company itself is not issuing new shares or receiving proceeds, the increased tradable supply creates an overhang for the stock. Despite the secondary offering, the company plans to repurchase 6 million shares and maintains solid fundamentals with growing revenue and positive free cash flow.
35M-share resale by LifeStance (NASDAQ: LFST) with 6M-share repurchase
LifeStance Health Group, Inc. (LFST) has filed a prospectus for the resale of 35,000,000 common shares by existing stockholders. While the company will not receive proceeds from these sales, it intends to repurchase 6,000,000 of the offered shares from the underwriter at the same price and retire them, funded by cash on hand. As of April 29, 2026, 387,834,432 shares were outstanding, with the last reported Nasdaq price at $7.36 on May 6, 2026.
LifeStance Health stock tumbles on secondary offering pricing
LifeStance Health Group Inc. (NASDAQ:LFST) shares dropped over 11% in premarket trading after the company announced the pricing of a secondary offering of 35 million shares at $8.15 each. The offering involves existing stockholders selling shares, with LifeStance not receiving any proceeds, though it will repurchase 6 million shares from the selling stockholders. J.P. Morgan is underwriting the transaction, expected to close around May 12, 2026.
Latest LFST News - LifeStance Health Announces Second Quarter ...
This page provides news and analysis for LifeStance Health Group (LFST), a mental healthcare company focusing on outpatient services. It covers quarterly earnings, financial outlooks, operational metrics, investor conference participation, and corporate governance updates. Recent news highlights include the announcement of second-quarter 2021 earnings release and details regarding its initial public offering in June 2021.
Press Release: LifeStance Health Group Announces Pricing of Secondary Public Offering
LifeStance Health Group, Inc. announced the pricing of a secondary public offering of 11,000,000 shares of its common stock at $9.95 per share. All shares are being offered by existing stockholders, and LifeStance will not receive any proceeds from the sale. The offering is expected to close around May 12, 2026, subject to customary conditions.
LifeStance Health Group, Inc. Stock 12‑Month Price Target Raised to $9.94, Implies 35% Upside
LifeStance Health Group, Inc.'s average 12-month price target has been increased to $9.94 from $9.83 by analysts, with a range of $8 to $12 per share. This target suggests a potential upside of approximately 35% from the May 6 closing price. The consensus rating for LFST remains a "Buy" among 10 analysts.
LifeStance (LFST) Hits 2-Year High as Q1 Profits Soar 1,900%
LifeStance Health Group Inc. (NASDAQ:LFST) reached a two-year high after reporting a 1,900% increase in Q1 net income to $14.2 million, with revenues rising 21% to $403.5 million. CEO Dave Bourdon attributed the strong performance to growing demand for mental healthcare. The company subsequently raised its full-year revenue growth forecast to $1.64 billion-$1.68 billion.
LifeStance Health Group Q1 2026 Earnings Call Transcript
LifeStance Health Group (LFST) reported an exceptional Q1 2026, with revenue up 21% to $403 million and adjusted EBITDA up 48% to $51 million, leading to a raised full-year guidance. The company added 309 clinicians, increasing visits by 18%, and is leveraging technology and AI for improved access and efficiency. Strategic growth focuses on de novo expansion and disciplined tuck-in M&A, alongside a strong commitment to clinical excellence and patient outcomes.
Why LifeStance Health Group Zoomed 20% Higher Today
LifeStance Health Group's stock surged over 20% after reporting a strong first quarter, significantly surpassing analyst expectations for revenue and net income. The outpatient mental health services provider saw a 21% revenue increase and a substantial rise in GAAP net income, prompting the company to raise its full-year guidance for both revenue and non-GAAP EBITDA, underscoring the growing demand for mental healthcare services.
LifeStance Health Group Announces Pricing of Secondary Public Offering
LifeStance Health Group, Inc. announced the pricing of a secondary public offering of 35,000,000 shares of its common stock at $8.15 per share. The offering is by certain Selling Stockholders, and LifeStance will not receive any proceeds. The company has also agreed to repurchase 6,000,000 shares from the underwriter, contingent on the offering's completion.
LifeStance holders offer 35M shares; company plans 6M buyback
LifeStance Health Group announced that certain selling stockholders intend to offer 35,000,000 shares of common stock in a secondary offering on May 7, 2026. The company will not sell shares or receive proceeds from this offering. Concurrently, LifeStance authorized a repurchase of 6,000,000 shares from the underwriter, J.P. Morgan, at the same per-share price, with no underwriting fees on the repurchased shares.
LifeStance Health Group Announces Launch of Secondary Public Offering
LifeStance Health Group, Inc. (Nasdaq: LFST) announced a secondary public offering where certain stockholders will sell 35,000,000 shares of common stock. The company will not receive any proceeds from this sale but concurrently plans to repurchase 6,000,000 shares from the underwriter at the same price. J.P. Morgan is acting as the underwriter for the offering.
LifeStance Health Group, Inc. 1Q 2026: Revenue $403.5M, EPS $0.04— 10-Q Summary
LifeStance Health Group, Inc. reported strong first-quarter 2026 results with revenue reaching $403.5 million, marking a 21% year-over-year increase, and net income significantly growing to $14.2 million. Diluted EPS stood at $0.04 for the quarter, up from $0 in the same period last year. The company's growth was attributed to an increase in patient visits, an expanded clinician base, and the successful scaling of its hybrid care model and operations.
Why Is LifeStance Health Group (LFST) Stock Rocketing Higher Today
LifeStance Health Group (LFST) shares surged 15.4% after reporting strong first-quarter 2026 financial results that exceeded Wall Street estimates, including a significant revenue increase and a surprise GAAP profit. The behavioral health company also provided optimistic guidance for the next quarter and raised its full-year forecasts, signaling confidence in its future performance. This positive news follows a recent gain when the company was added to the S&P SmallCap 600 index.
LifeStance (NASDAQ: LFST) posts 21% Q1 growth and hikes 2026 guidance
LifeStance Health Group (NASDAQ: LFST) reported a strong first quarter for 2026, with revenue increasing 21% to $403.5 million, driven by higher visit volumes and an expanded clinician base. Net income significantly improved to $14.2 million, and Adjusted EBITDA grew by 48% to $51.1 million. Based on this performance, the company raised its full-year 2026 guidance for revenue, Center Margin, and Adjusted EBITDA, demonstrating confidence in continued growth and profitability.
LifeStance Health Group Releases Q1 2026 Financial Results
LifeStance Health Group (LFST) announced strong Q1 2026 financial results, with diluted EPS of $0.04 significantly beating Wall Street estimates of $0.01, a 300% beat. The company reported revenue of $403.5M, a 21.0% increase from Q1 2025, driven by robust demand for behavioral health services and an expanded network of 8,349 clinicians. Management projects full-year revenue between $1.64B and $1.68B, and analysts maintain a positive outlook with 9 buy ratings.
LifeStance Health: Q1 Earnings Snapshot
LifeStance Health Group Inc. (LFST) reported a first-quarter profit of $14.2 million, or 4 cents per share, surpassing Wall Street expectations of 1 cent per share. The company also exceeded revenue forecasts, posting $403.5 million against an anticipated $388.2 million. LifeStance Health provided guidance, expecting revenue between $405 million and $425 million for the current quarter and $1.64 billion to $1.68 billion for the full year.
LifeStance Reports First Quarter 2026 Results
LifeStance Health Group, Inc. reported strong first quarter 2026 results, with revenue increasing by 21% to $403.5 million and net income rising significantly to $14.2 million. The company's clinician base grew to 8,349, and visit volumes increased by 18%. LifeStance also raised its full-year 2026 guidance for revenue, Center Margin, and Adjusted EBITDA, reflecting confidence in its continued growth and operational efficiency.
LifeStance Health Group (NASDAQ:LFST) Surprises With Strong Q1 CY2026
LifeStance Health Group (NASDAQ:LFST) reported a strong Q1 CY2026, beating Wall Street's revenue and EPS expectations with sales up 21.2% year-on-year to $403.5 million and a GAAP profit of $0.04 per share. The company also provided surprisingly good revenue and EBITDA guidance for the next quarter and the full year, indicating healthy demand and improved efficiency. Following the report, the stock traded up 4.4%.
LifeStance Health: Q1 Earnings Snapshot
LifeStance Health Group Inc. (LFST) reported a first-quarter profit of $14.2 million, or 4 cents per share, surpassing Wall Street expectations. The outpatient mental health services provider also exceeded revenue forecasts, posting $403.5 million for the quarter. The company projects Q2 revenue between $405 million and $425 million, with full-year revenue estimated to be between $1.64 billion and $1.68 billion.
How Investors Are Reacting To LifeStance Health Group (LFST) Joining Key S&P Small‑Cap Health Indices
LifeStance Health Group (LFST) was recently added to several S&P indices, including the S&P 600 and Composite 1500, which is expected to increase its visibility among institutional investors. This inclusion reinforces the company's investment narrative, focusing on its large outpatient clinician network and execution on profitable growth. However, investors need to also consider potential risks like reimbursement pressures and competition from tech-enabled health providers.
